Clinical trial · Interventional
Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
A Randomized, Open-label, Multicenter Study Comparing the Efficacy and Safety of NRT6003 Injection With Conventional Transarterial Chemoembolization (cTACE) in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)
NCT06900543CI-TRIAL-00114038CHEERSactive not recruitingPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to evaluate the efficacy and safety of NRT6003 Injection compared to cTACE in patients with unresectable HCC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Unresectable Hepatocellular Carcinoma | Hepatocellular Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cTACE | Drug | — | UNRESOLVED |
| NRT6003 Injection | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- NRT6003 Injection
- description
- Selective internal radiation therapy (SIRT) with TareSphere
- interventionNames
- Drug: NRT6003 Injection
- type
- ACTIVE_COMPARATOR
- label
- cTACE
- description
- Transarterial chemoembolization
- interventionNames
- Drug: cTACE
Primary outcomes (1)
- measure
- Time to Progression (TTP)
- timeFrame
- Through study completion, at least 18 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Key Inclusion Criteria: 1. Diagnosed as hepatocellular carcinoma (CNLC Ⅰa-Ⅲa) clinically, by imaging and/or pathology based on the guideline of the National Health Commission of the People's Republic of China (2024). 2. Evaluated by the investigator as not suitable for surgical resection/ablation/liver transplantation, or there is high risk for surgical resection, or the participant refuses surgical resection/ablation/liver transplantation. 3. Child-Pugh score ≤ 7. 4. Eastern Cooperative Oncology Group performance status ≤ 1. 5. Adequate organ function. Key Exclusion Criteria: 1. Imaging evidence or suspicion of extrahepatic metastases (including regional lymph node metastases). 2. Prior antitumor treatment for primary hepatocellular carcinoma. 3. Prior external radiation therapy or intra-arterial brachytherapy. 4. Liver vascular evaluation results that do not meet all the requirements of the study.
References
Publications (0)
Data not yet available
No reference posted for this study.